Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL1644459 | 0.97 | KMT2A (0.42) | KMT2AMEN1F2PRSS1PRSS2 | |
| Guanidine SCHEMBL1643693 | 0.75 | GAA (0.50) | KMT2AMEN1PRSS1PRSS2PRSS3 | |
| SCHEMBL1644916 | 0.74 | CYP3A4 (0.51) | KMT2AMEN1MAPTTDP1CYP1A2 | |
| SCHEMBL3161586 | 0.73 | GPR35 (0.51) | KMT2AMEN1MAPK1TDP1CYP1A2 | |
| Guanidine SCHEMBL1644457 | 0.73 | GAA (0.47) | KMT2AMEN1PRSS1PRSS2PRSS3 | |
| Nitric Acid SCHEMBL1644176 | 0.73 | ALDH1A1 (0.52) | KMT2AMEN1F2PRSS1PRSS2 | |
| SCHEMBL9683795 | 0.71 | TDP1 (0.50) | KMT2AMEN1PRSS1PRSS2PRSS3 | |
| SCHEMBL7080582 | 0.71 | CYP1A2 (0.57) | KMT2AMEN1MAPTMAPK1TDP1 | |
| SCHEMBL30496244 | 0.71 | CYP1A2 (0.57) | KMT2AMEN1MAPTMAPK1TDP1 | |
| SCHEMBL17182634 | 0.70 | ALDH1A1 (0.47) | KMT2AMEN1MAPTTDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110097268-A1 | RADIOHALOIMATINIBS AND METHODS OF THEIR SYNTHESIS AND USE IN PET IMAGING OF CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-04-28 | — | — | US | disclosed |
| WO-2008024829-A2 | RADIOHALOIMATINIBS AND METHODS OF THEIR SYNTHESIS AND USE IN PET IMAGING OF CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097268-A1 | RADIOHALOIMATINIBS AND METHODS OF THEIR SYNTHESIS AND USE IN PET IMAGING OF CANCERS | ROS1, HRAS, MYC | KMT2A 781/4885MEN1 778/4885F2 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.